Literature DB >> 27080184

A review on ROCK-II inhibitors: From molecular modelling to synthesis.

Surmil Shah1, Jignasa Savjani2.   

Abstract

Rho kinase enzyme expressed in different disease conditions and involved in mediating vasoconstriction and vascular remodeling in the pathogenesis. There are two isoforms of Rho kinases, namely ROCK I and ROCK II, responsible for different physiological function due to difference in distribution, but almost similar in structure. The Rho kinase 2 belongs to AGC family and is widely distributed in brain, heart and muscles. It is responsible for contraction of vascular smooth muscles by calcium sensitization. Its defective and unwanted expression can lead to many medical conditions like multiple sclerosis, myocardial ischemia, inflammatory responses, etc. Many Rho kinase 1 and 2 inhibitors have been designed for Rho/Rho kinase pathway by use of molecular modeling studies. Most of the designed compounds have been modeled based on ROCK 1 enzyme. This article is focused on Rho kinase 2 inhibitors as there are many ways to improvise by use of Computer aided drug designing as very less quantum of research work carried out. Herein, the article highlights different stages of designing like docking, SAR and synthesis of ROCK inhibitors and recent advances. It also highlights future prospective to improve the activity.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Docking; Regulation; Rho kinase-2 (ROCK-2) inhibitors; SAR; Synthesis

Mesh:

Substances:

Year:  2016        PMID: 27080184     DOI: 10.1016/j.bmcl.2016.03.113

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

Review 1.  Actin dynamics in the regulation of endothelial barrier functions and neutrophil recruitment during endotoxemia and sepsis.

Authors:  Michael Schnoor; Alexander García Ponce; Eduardo Vadillo; Rosana Pelayo; Jan Rossaint; Alexander Zarbock
Journal:  Cell Mol Life Sci       Date:  2017-02-02       Impact factor: 9.261

2.  In silico prediction of ROCK II inhibitors by different classification approaches.

Authors:  Chuipu Cai; Qihui Wu; Yunxia Luo; Huili Ma; Jiangang Shen; Yongbin Zhang; Lei Yang; Yunbo Chen; Zehuai Wen; Qi Wang
Journal:  Mol Divers       Date:  2017-08-02       Impact factor: 2.943

3.  Identification of Novel Rho-Kinase-II Inhibitors with Vasodilatory Activity.

Authors:  Seema Kesar; Sarvesh Paliwal; Pooja Mishra; Kirtika Madan; Monika Chauhan; Neha Chauhan; Kanika Verma; Swapnil Sharma
Journal:  ACS Med Chem Lett       Date:  2020-08-04       Impact factor: 4.345

Review 4.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

5.  Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells.

Authors:  Yong Wang; Yueyang Zhang; Tao Yang; Wei Zhao; Ningning Wang; Pengcheng Li; Xiandong Zeng; Weiguo Zhang
Journal:  Oncotarget       Date:  2017-07-31

6.  The Design, Synthesis and Evaluation of Rho-kinase Inhibitory Activity of 4-aryl-thiazole-2-amines.

Authors:  Linan Wang; Ben Ouyang; Meixia Fan; Junhui Qi; Lei Yao
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

7.  Fam65b Phosphorylation Relieves Tonic RhoA Inhibition During T Cell Migration.

Authors:  Laura Megrelis; Elyas El Ghoul; Federica Moalli; Margaux Versapuech; Shamir Cassim; Nora Ruef; Jens V Stein; Marianne Mangeney; Jérôme Delon
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.